Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 and ....
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed the stock exchanges that a Board of Directors meeting is scheduled for Wednesday, May 21, 2025. The main agenda is to consider and approve both standalone and consolidated audited financial results for the quarter and full financial year ended March 31, 2025. This is a standard regulatory disclosure under SEBI's Listing Obligations. The trading window for dealing in the company's shares will remain closed till May 23, 2025, as part of insider trading prevention rules. No financial figures or business decisions have been disclosed in this filing.
This is a routine pre-results intimation and does not contain any material business information. Shareholders should wait for the actual Q4 and FY25 results on May 21, 2025 for any meaningful insight into the company's performance or stock direction.